Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease

NCT04239625 is registered in ClinicalTrials.gov with Alkeus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04239625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04239625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 20, 2019
Completion date
December 31, 2029
Enrollment
200 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal recessive stargardt disease 1 (abca4-related), stargardt disease, stargardt macular degeneration, stargardt macular dystrophy